Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Randomized Controlled Trial
[키워드] 1:1
95% CI
acute respiratory syndrome
adjusted
age
analysed
Analysis
assigned
AstraZeneca
AZD1222
blinded
both group
Brazil
calculated
ChAdOx1 nCoV-19
ChAdOx1 nCoV-19 vaccine
Clinical research
clinical trials
Coalition
Cohort
contribute
control group
Controlled trial
coronavirus
Coverage
COVID-19
COVID-19 pandemic
Cutoff
death
dose
doses
Efficacy
efficacy analysis
enrolled
evaluated
event
finding
first dose
Follow-up
foundation
funding
hospitalised
include
Innovation
Interaction
interim analysis
IQR
ISRCTN89951424
low dose
median
Melinda Gate
network
NIHR
nucleic acid amplification
occurred
Older
Oxford
participant
Participants
Poisson regression model
randomised
randomised controlled trial
Randomly
Registered
risk
robust
Safe
Safety
safety profile
SARS-CoV-2
second dose
seronegative participant
severe adverse event
severe COVID-19
South
South Africa
Standard dose
subset
Swab
symptomatic
Telle
Treatment
Trial
trials
Vaccine
vaccine efficacy
Valley
viral particle
[DOI] 10.1016/S0140-6736(20)32661-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/S0140-6736(20)32661-1 PMC 바로가기 [Article Type] Randomized Controlled Trial